Andarine
S-4 — The First-Generation Clinical SARM
01
Overview
Andarine (S-4, GTx-007) is a non-steroidal selective androgen receptor modulator developed by GTx Inc. as one of the earliest SARMs to enter preclinical development. It demonstrates moderate anabolic activity in muscle and bone with reduced androgenic effects in prostate. Research applications include muscle wasting, benign prostatic hyperplasia, and osteoporosis.
02
Mechanism of Action
Andarine binds the androgen receptor with moderate affinity (Ki ~4 nM), demonstrating tissue-selective partial agonism. It activates anabolic gene programs in muscle and bone while acting as a partial agonist in prostate tissue, resulting in a favorable anabolic-to-androgenic ratio. Its short half-life produces rapid onset and clearance.
03
Research Highlights
Ovariectomized rat models show improved bone mineral density and reduced osteoporosis markers
Cachexia research demonstrates lean mass preservation with minimal prostate enlargement
Tissue selectivity profiling confirms partial agonist activity in prostate versus full agonism in muscle
04
Dosage
Administration & Timing
Oral administration (capsule or solution), once or twice daily. Research protocols administer independent of food.
Dosage Guidelines
Cycle Length
6–8 weeks; followed by 4 week rest and PCT evaluation.
05
Reconstitution
Solvent
Not applicable — orally dosed capsule or solution
Volume
N/A
Concentration
25–50 mg total daily dose
Storage
Store at room temperature (15–25 °C); protect from moisture.
Notes
Andarine (S4) is notable for a vision-related side effect (yellow tint, altered night vision) at higher doses — resolve on discontinuation.
Research Reference Only
Dosage and reconstitution values reflect commonly cited ranges from published research literature and are presented for educational and research reference only. This is not medical advice or a dosing recommendation. HEXAGEN does not endorse human use of any compound. Always consult a qualified healthcare professional.
Research Disclaimer
Andarine is for educational and research purposes only. Not intended as medical advice. Consult a qualified healthcare professional before making any health-related decisions.
Related Compounds
View All
Andarine Knowledge Graph
Explore how Andarine connects to mechanisms, research goals, related compounds, research stacks, and scientific references. Drag nodes, zoom, and filter by type.
No nodes match the active filters.
Andarine — Common Research Questions
What is Andarine?
Andarine (S-4, GTx-007) is a non-steroidal selective androgen receptor modulator developed by GTx Inc. as one of the earliest SARMs to enter preclinical development. It demonstrates moderate anabolic ... Andarine belongs to the Non-Peptide Research research category and is studied for its s-4 — the first-generation clinical sarm.
How does Andarine work?
Andarine binds the androgen receptor with moderate affinity (Ki ~4 nM), demonstrating tissue-selective partial agonism. It activates anabolic gene programs in muscle and bone while acting as a partial agonist in prostate tissue, resulting in a favorable anabolic-to-androgenic ratio. Its short half-life produces rapid onset and clearance.
What are the key research benefits of Andarine?
Moderate anabolic activity in skeletal muscle. Bone mineral density improvement in research. Reduced prostate androgenic stimulation. Muscle wasting and cachexia research. Benign prostatic hyperplasia research applications. Established preclinical safety dataset.
What is the molecular structure of Andarine?
Andarine is a research compound in the Non-Peptide Research category. Detailed molecular structure data is being compiled. Refer to primary literature for structural analysis.
What does the research say about Andarine?
Ovariectomized rat models show improved bone mineral density and reduced osteoporosis markers Cachexia research demonstrates lean mass preservation with minimal prostate enlargement Tissue selectivity profiling confirms partial agonist activity in prostate versus full agonism in muscle These findings are based on preclinical and clinical research. Andarine is a research compound and these studies do not constitute medical advice.
Is Andarine FDA approved?
No. Andarine is not FDA-approved for any indication. It is a research chemical studied in preclinical and early clinical research. These compounds are not approved for human therapeutic use and should only be studied in appropriate research settings.
What category does Andarine belong to?
Andarine belongs to the Non-Peptide Research category, which focuses on selective androgen receptor modulators and other novel research compounds studied for their unique pharmacological profiles. You can explore more compounds in this category on the Non-Peptide Research pillar page.
Related Articles
RAD-140 (Testolone): Selective Anabolic Activity
Examining RAD-140's tissue-selective androgen receptor binding and its Phase I breast cancer research.
Cardarine (GW501516): PPARδ and Exercise Mimetics
How Cardarine activates PPARδ to drive fatty acid oxidation and its implications for endurance research.
LGD-4033 (Ligandrol): Phase I Clinical Data
Viking Therapeutics' Phase I trial showing dose-dependent lean mass gains and the VK5211 hip fracture study.
Scientific References
Ovariectomized rat models show improved bone mineral density and reduced osteoporosis markers
Cachexia research demonstrates lean mass preservation with minimal prostate enlargement
Tissue selectivity profiling confirms partial agonist activity in prostate versus full agonism in muscle